CTRV - ContraVir Pharmaceuticals Inc.

3.58
3.580   100.000%

Share volume: 0
Last Updated: 07-22-2019

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Historical prices Events Documents Notes Dividends
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$3.58
P/E Ratio 
N/A
DAY RANGE
$3.58 - $3.58
EPS 
-$88.10
52 WEEK RANGE
$3.52 - $91.00
52 WEEK CHANGE
-$94.63
MARKET CAP 
2.875 M
YIELD 
N/A
SHARES OUTSTANDING 
803.000 K
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$11,338
AVERAGE 10 VOLUME 
$394,557
AVERAGE 30 VOLUME 
$1,182,789
Company detail
CEO: Robert T. Foster
Region: US
Website: http://www.contravir.com
Employees: 14
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry:
Sector:

ContraVir Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.

Recent news